Teva buys unit from Botox maker Allergan

Israeli drugmaker Teva Pharmaceuticals has agreed to buy the generic-drug business of Allergan for about $40.5bn (€36.8bn) in cash and stock, ending its hostile bid for rival Mylan.

Teva buys unit from Botox maker Allergan

The deal does not include Allergan’s anti-wrinkle treatment Botox plant in Westport, Co Mayo, or another manufacturing plant and a European shared-services centre in Dublin.

Allergan employs about 1,000 people across those three operations.

You have reached your article limit. Already a subscriber? Sign in

Continue reading for €5

Unlock unlimited access and exclusive benefits

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited